Castlevax INC
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersNew York, NY
SAM.gov UEIFLZ6THBQ53N3
CastleVax develops mucosal vaccines using a platform based on Newcastle Disease Virus (NDV) as a viral vector. The company is in clinical-stage development with a COVID-19 vaccine candidate currently in Phase 2 testing. The platform is designed to enable rapid development of vaccines for respiratory diseases delivered through mucosal routes rather than systemic delivery.
Summarized from the company’s own website
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Castlevax INC | New York | NY | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.